Rachel Lane PhD is the Senior Vice President of Business Development and Operations. She brings over a decade of leadership experience across the biotech industry as an executive, investor, and board director. Most recently, she served as Chief Business Officer at Belharra Therapeutics, where she architected and closed multiple major transactions, including flagship platform partnerships with Genentech and Sanofi. Prior to Belharra, she was a member of the core investment team at Versant Ventures and Chief Business Officer at Inception Therapeutics, Versant’s West Coast NewCo incubator. Earlier in her career, Rachel held diverse roles across the industry, including business development positions at Calico Life Sciences and Ovid Therapeutics, early-stage investing at the Alzheimer’s Drug Discovery Foundation, and as a Wall Street sell-side analyst. She has held multiple board roles and currently serves on the board of directors of Belharra Therapeutics. Rachel is a neurobiologist by training. She earned her PhD in cell and molecular biology from the University of Sheffield and completed postdoctoral training in neurobiology at the Icahn School of Medicine at Mount Sinai in New York.